Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Virus provided with gene cooperation element and applications of virus

An element and gene technology, which is applied to viruses with gene synergistic elements and their application fields, can solve the problem of low efficacy of the virus, and achieve the effect of obvious advantages, optimized structure, and good disease prevention or treatment effect.

Inactive Publication Date: 2017-02-01
黄朝述
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to overcome the problem of low virus curative effect in the prior art, to provide a virus with gene synergistic elements that can better actively and effectively stimulate the body's specific immunity, and then better exert the effect of disease prevention or treatment, and The application of the virus with gene synergistic elements is disclosed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Virus provided with gene cooperation element and applications of virus
  • Virus provided with gene cooperation element and applications of virus
  • Virus provided with gene cooperation element and applications of virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Viruses with gene coordination elements consist of promoter one, replicon replication gene, tag protein, promoter two, cytokine sequence, heat shock protein sequence HSPs, CpG motif, PolyA sequence, tailing signal sequence, Promoter three, vector replication gene, tailing signal sequence, which are inserted into the viral vector together, are called Ad-SFV-ABC-E1A, and its structure is as follows figure 1 Shown.

[0042] Among them, the virus vector uses adenovirus pShuttle-CMV vector, and uses BglII-HindIII for restriction digestion. The gene sequence at both ends of the insertion site after restriction digestion is as follows:

[0043] 5'-...CATCATCAATATTATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTTATGGAGTTTGTCAC-3';

[0044] 5'-AACGCGGATCTGGGCGTGGTTAAGGGTGGGAAAGAATATATAAGGT GGGGGTCTTATG...-3'.

[0045] In this embodiment, the promoter one uses mEF1 promoter-BglII, the replicon replication gene is composed of the pSFV gene sequence obtained after the alphavirus replicon is dig...

Embodiment 2

[0055] The difference between this embodiment and embodiment 1 lies in: this embodiment removes part of the gene sequence from the Ad-SFV-ABC-E1A described in embodiment 1, and the specific settings are as follows:

[0056] Tumor drug group 1: Ad-SFV-ABC-E1A.

[0057] Tumor Drug Group 2: Remove the CpG motif on the basis of Ad-SFV-ABC-E1A, the CpG motif is a CpG island, and the sequence of the CpG island is shown in SEQ ID NO: 2;

[0058] Oncology drug group 3: On the basis of Ad-SFV-ABC-E1A, the heat shock protein sequence HSPs are removed, and the heat shock protein sequence HSPs is Mycobacterium bovis HSP70. The sequence of M. tuberculosis HSP70 is as SEQ ID NO: 3 shown;

[0059] Tumor drug group 4: On the basis of Ad-SFV-ABC-E1A, the cytokine sequence is removed, the cytokine sequence is mGM-CSF, and the sequence of mGM-CSF is shown in SEQ ID NO: 4;

[0060] Oncology drug group 5: remove the heat shock protein sequence HSPs and CpG motifs on the basis of Ad-SFV-ABC-E1A;

[0061] Tum...

Embodiment 3

[0075] The difference between this embodiment and embodiment 1 is that the virus of this embodiment does not include a vector-specific replication unit, and the GFP sequence is replaced with the mouse parvovirus MVM-VP2. The specific sequence of the MVM-VP2 in this embodiment The structure is shown in SEQ ID NO: 5, and the gene sequence of the vector-specific replication unit is shown in SEQ ID NO: 6.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a virus provided with a gene cooperation element and applications of the virus. The virus comprises a virus carrier, wherein a virus replicon and a carrier specific duplication unit are inserted on the virus carrier, the virus replicon comprises a replicon replicator, a promoter I used for starting transcription and translation of the replicon replicator, the gene cooperation element connected to the replicon replicator, and a tailing signal sequence arranged at the tail end of the virus replicon; the gene cooperation element is composed of one or more of a cell factor sequence, a heat shock protein sequence HSPs and a CpG sequence motif, and the gene cooperation element is further provided with a promoter II used for starting the transcription and translation of the gene cooperation element. The virus can well initiatively and effectively stimulate the specific immunity of the body, so that the effect of preventing or treating diseases is well achieved.

Description

Technical field [0001] The present invention relates to a virus, in particular to a virus with gene cooperative elements and its application. Background technique [0002] There are two types of published patents with similar technical principles. One is targeted viruses. As recorded in patents CN2004800131515 and CN2014101476528, targeted viruses can replicate specifically in tumor cells and must be targeted for tumor administration to achieve a certain therapeutic effect. , Use viruses to directly kill tumor cells. This technology uses adenovirus as a carrier and adds some apoptosis genes to cause tumor cell death. The adenovirus can replicate in tumor cells specifically, but the limitation of this technology is that the targeted virus is easily recognized and killed by the body's antibodies And fail. This technology can induce and enhance the tumor-specific immunity of the body. [0003] The other type is the adenovirus alphavirus hybrid vector, as described in patents CN2005...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N7/01C12N15/861C12N15/863C12N15/869C12N15/867C12N15/12C12N15/20C12N15/24C12N15/26C12N15/27A61K35/761A61K35/763A61K35/768A61K48/00A61K38/20A61K38/19A61K38/21A61K38/16A61P35/00A61P37/04
CPCC12N7/00A61K35/761A61K35/763A61K35/768A61K38/164A61K38/193A61K38/20A61K38/2013A61K38/202A61K38/2086A61K38/21A61K48/0008A61K48/0058C07K14/47C07K14/53C07K14/535C07K14/54C07K14/5403C07K14/5409C07K14/5443C07K14/55C07K14/555C12N15/86C12N2710/10021C12N2710/10041C12N2710/16021C12N2710/16041C12N2710/24021C12N2710/24041C12N2740/10021C12N2740/10041C12N2740/15021C12N2740/15041C12N2750/14121C12N2750/14141A61K2300/00
Inventor 黄朝述
Owner 黄朝述
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com